Drugs that contain Ripretinib

1. List of Qinlock drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188113 DECIPHERA PHARMS Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jul, 2030

(7 years from now)

US8461179 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48731 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(9 years from now)

US11266635 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US10966966 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11433056 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11344536 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11426390 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Aug, 2040

(17 years from now)

US11185535 DECIPHERA PHARMS Amorphous kinase inhibitor formulations and methods of use thereof
Dec, 2040

(17 years from now)

US11395818 DECIPHERA PHARMS Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
Dec, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 15, 2025
Orphan Drug Exclusivity (ODE) May 15, 2027

NCE-1 date: May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumor; Treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome; Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib; Method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily; Treatment of gastrointestinal stromal tumors in patients suffering from hypertension; Treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in